JP2022500047A5 - - Google Patents
Info
- Publication number
- JP2022500047A5 JP2022500047A5 JP2021514036A JP2021514036A JP2022500047A5 JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5 JP 2021514036 A JP2021514036 A JP 2021514036A JP 2021514036 A JP2021514036 A JP 2021514036A JP 2022500047 A5 JP2022500047 A5 JP 2022500047A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- genetically modified
- rat
- microns
- compared
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730690P | 2018-09-13 | 2018-09-13 | |
| US62/730,690 | 2018-09-13 | ||
| PCT/US2019/050792 WO2020056122A1 (en) | 2018-09-13 | 2019-09-12 | Complement factor h gene knockout rat as a model of c3 glomerulopathy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500047A JP2022500047A (ja) | 2022-01-04 |
| JP2022500047A5 true JP2022500047A5 (https=) | 2022-09-01 |
| JPWO2020056122A5 JPWO2020056122A5 (https=) | 2022-09-01 |
| JP7222075B2 JP7222075B2 (ja) | 2023-02-14 |
Family
ID=68052023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514036A Active JP7222075B2 (ja) | 2018-09-13 | 2019-09-12 | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220053741A1 (https=) |
| EP (1) | EP3849304B1 (https=) |
| JP (1) | JP7222075B2 (https=) |
| KR (1) | KR102545031B1 (https=) |
| CN (1) | CN112969367B (https=) |
| AU (1) | AU2019339404B2 (https=) |
| CA (1) | CA3112612C (https=) |
| ES (1) | ES2974200T3 (https=) |
| WO (1) | WO2020056122A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202010009D0 (en) * | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| CN114634932B (zh) * | 2022-03-11 | 2023-09-05 | 安徽医科大学 | 一种新circRNA、试剂盒及用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8587598A (en) | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| EP2386316B1 (en) * | 2004-06-10 | 2018-02-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| EP2357254A1 (en) * | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
| WO2009126161A1 (en) | 2008-04-11 | 2009-10-15 | Utc Fuel Cells, Llc | Fuel cell and bipolar plate having manifold sump |
| WO2010027872A1 (en) * | 2008-08-27 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis |
| US20120159653A1 (en) * | 2008-12-04 | 2012-06-21 | Sigma-Aldrich Co. | Genomic editing of genes involved in macular degeneration |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| GB0922659D0 (en) * | 2009-12-24 | 2010-02-10 | Univ Edinburgh | Factor H |
| IN2014DN09261A (https=) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2014033644A2 (en) | 2012-08-28 | 2014-03-06 | Novartis Ag | Methods of nuclease-based genetic engineering |
| EP3363902B1 (en) | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| MX2015010841A (es) | 2013-02-20 | 2016-05-09 | Regeneron Pharma | Modificacion genetica de ratas. |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| US10183988B2 (en) * | 2013-06-07 | 2019-01-22 | Duke University | Anti-Complement factor H antibodies |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| ES2731437T3 (es) | 2014-11-21 | 2019-11-15 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías |
| WO2017114401A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
| CN106519030B (zh) * | 2016-12-22 | 2020-01-07 | 广州泰诺迪生物科技有限公司 | 补体因子h抑制剂及与之相关的用途 |
| CN118184777A (zh) * | 2017-01-30 | 2024-06-14 | 亚力兄制药公司 | 单价抗备解素抗体及抗体片段 |
| US10765762B2 (en) * | 2017-02-27 | 2020-09-08 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
-
2019
- 2019-09-12 JP JP2021514036A patent/JP7222075B2/ja active Active
- 2019-09-12 CA CA3112612A patent/CA3112612C/en active Active
- 2019-09-12 CN CN201980071118.4A patent/CN112969367B/zh active Active
- 2019-09-12 EP EP19773717.4A patent/EP3849304B1/en active Active
- 2019-09-12 AU AU2019339404A patent/AU2019339404B2/en active Active
- 2019-09-12 ES ES19773717T patent/ES2974200T3/es active Active
- 2019-09-12 US US17/275,096 patent/US20220053741A1/en active Pending
- 2019-09-12 KR KR1020217010579A patent/KR102545031B1/ko active Active
- 2019-09-12 WO PCT/US2019/050792 patent/WO2020056122A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sequeira-Lopez et al. | The microRNA-processing enzyme dicer maintains juxtaglomerular cells | |
| US12471579B2 (en) | Mouse model of DITRA disease and uses thereof | |
| JP2021500864A5 (https=) | ||
| JP2020501582A5 (https=) | ||
| KR102602199B1 (ko) | 신장 및 간 장애의 인간화 모델 | |
| Paratz et al. | Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon? | |
| JP7473548B2 (ja) | Ｍｍａの処置のための非破壊的遺伝子治療 | |
| US20180084767A1 (en) | Animal models for cardiomyopathy | |
| CN112011538A (zh) | 一种Mutyh基因条件性敲除小鼠模型的构建方法 | |
| US7960606B2 (en) | Mouse model of chronic heart failure and coronary atherosclerosis regression | |
| Hashikami et al. | Establishment of X-linked Alport syndrome model mice with a Col4a5 R471X mutation | |
| JP2022500047A5 (https=) | ||
| Aweidah et al. | PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation | |
| WO2013188358A1 (en) | Miniature swine transgenic for one or more coagulation factors | |
| CN111485003B (zh) | 一种视网膜血管疾病模型的构建方法及其应用 | |
| CN116676338A (zh) | 一种遗传型转甲状腺素蛋白淀粉样变疾病模型的构建方法及应用 | |
| US20210268019A1 (en) | Targeted expression of microbial cholesterol catalysis genes reduces excess lipid | |
| JP7222075B2 (ja) | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット | |
| Ding et al. | Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen | |
| JPWO2020056122A5 (https=) | ||
| CN115838768A (zh) | 一种基因敲除能够引起癫痫症状发生的动物模型构建的方法及应用 | |
| KR20220150295A (ko) | B4galt1-매개 기능의 설치류 모델 | |
| CN114107400B (zh) | 一种视网膜血管疾病模型的构建方法及其应用 | |
| US20260078368A1 (en) | Methods and compositions for treating pancreatic cancer | |
| CN116064526B (zh) | 靶向stat3基因的向导rna、试剂盒、方法及应用 |